Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...

In the intent-to-treat population, the median OS was 13.2 months with daraxonrasib vs 6.7 months for chemotherapy, ...

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety ...

Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and ...

In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline ...

In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior ...

Lilit Karapetyan of the Moffitt Cancer Center details a significant shift in clinical confidence regarding the treatment of ...

O'Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center discussed the rationale and early progress of a phase 1/2 ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with ...

Nodal burden predicts higher preoperative ctHPVDNA levels, while aggressive pathologic features paradoxically correlate with ...